<DOC>
	<DOCNO>NCT02796157</DOCNO>
	<brief_summary>PCI diffuse long coronary lesion still remain challenge relatively high risk in-stent restenosis stent thrombosis compare short coronary lesion . The purpose study compare incidence composite major adverse cardiovascular event ( MACEs ) 1 year Absorb everolimus-eluting BVS Xience EES coronary intervention long lesion 28 mm .</brief_summary>
	<brief_title>A Randomized Comparison Clinical Outcomes Between Everolimus-eluting Bioresorbable Vascular Scaffold Versus Everolimus-eluting Metallic Stent Long Coronary Lesions</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Age 1985 year Patients ischemic heart disease require PCI Significant coronary de novo lesion ( stenosis &gt; 50 % quantitative angiographic analysis ) require stent â‰¥28 mm length base angiographic estimation Reference vessel diameter 2.5 3.75 mm operator assessment Acute myocardial infarction within 48 hour unstable hemodynamics require pharmacologic mechanical support Complex coronary morphology include leave main disease bifurcation lesion require twostent technique Contraindication hypersensitivity antiplatelet agent contrast medium Treated metallic stent BVS within 3 month vessel Cardiogenic shock Left ventricular ejection fraction &lt; 40 % Pregnant woman woman potential childbearing Inability follow patient period 1 year enrollment , assess investigator Inability understand read inform content</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>bioresorbable vascular scaffold , drug elute stent , coronary artery disease</keyword>
</DOC>